Morgan Stanley Pulmonx Corp Call Options Transaction History
Morgan Stanley
- $1.49 Trillion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding LUNG
# of Institutions
120Shares Held
33.9MCall Options Held
0Put Options Held
0-
Primecap Management CO Pasadena, CA5.16MShares$9.5 Million0.01% of portfolio
-
Black Rock Inc. New York, NY2.67MShares$4.91 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.29MShares$4.22 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY1.89MShares$3.48 Million0.11% of portfolio
-
Jefferies Group LLC New York, NY1.2MShares$2.21 Million0.2% of portfolio
About Pulmonx Corp
- Ticker LUNG
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 37,268,400
- Market Cap $68.6M
- Description
- Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a ...